AstraZeneca PLC (AZN)vsOwlet Inc (OWLT)
AZN
AstraZeneca PLC
$186.43
-0.22%
HEALTHCARE · Cap: $263.78B
OWLT
Owlet Inc
$4.17
-1.65%
HEALTHCARE · Cap: $121.85M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 53536% more annual revenue ($61.37B vs $114.41M). AZN leads profitability with a 17.0% profit margin vs -8.4%. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
OWLT
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$186.43
$8.53 discount
Intrinsic value data unavailable for OWLT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Revenue surging 29.9% year-over-year
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -526.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : OWLT
The strongest argument for OWLT centers on Debt/Equity, Revenue Growth. Revenue growth of 29.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while OWLT is a growth play — different risk/reward profiles.
OWLT carries more volatility with a beta of 2.22 — expect wider price swings.
OWLT is growing revenue faster at 29.9% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 37/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a leading innovator in infant health technology, dedicated to enhancing the safety and wellness of newborns through its state-of-the-art monitoring solutions. The company's flagship product, the Owlet Smart Sock, employs advanced pulse oximetry to provide parents with real-time insights into their infants' heart rates and oxygen levels via mobile devices. With growing demand for pediatric health monitoring solutions, Owlet is well-positioned to expand its product offerings and fortify its market presence. The company's focus on delivering actionable health information and improving pediatric care aligns with institutional investors' interests in the dynamic health technology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?